Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Rodriguez Gutierrez D
  • Jones C
  • Varlet P
  • Mackay A
  • Warren D
  • Warmuth-Metz M
  • Sánchez Aliaga E
  • Calmon R
  • Hargrave DR
  • Massimino M
  • Azizi AA
  • Le Deley MC
  • Saran F
  • Rousseau RF
  • Zahlmann G
  • Garcia J
  • Vassal G
  • Grill J
  • Morgan PS
  • Jaspan T

Grupos

Abstract

The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathological and molecular data.

Datos de la publicación

ISSN/ISSNe:
1078-0432, 1557-3265

CLINICAL CANCER RESEARCH  AMER ASSOC CANCER RESEARCH

Tipo:
Article
Páginas:
1856-1865
PubMed:
31924736
Factor de Impacto:
5,427 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 14

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Compartir